Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs

Blood Advances · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles